2,3,4,5-Tetrahydro-1-benzoxepin-2-carbonsaeure | 103988-33-6

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 2,3,4,5-Tetrahydro-1-benzoxepin-2-carbonsaeure
• 英文别名: 2,3,4,5-tetrahydro-benzo[b]oxepine-2-carboxylic acid；2,3,4,5-tetrahydro-benz[b]oxepin-2-carboxylic acid；2,3,4,5-Tetrahydro-benz[b]oxepin-2-carbonsaeure；NoName_516；2,3,4,5-tetrahydro-1-benzoxepine-2-carboxylic acid
• CAS: 103988-33-6
• 化学式: C₁₁H₁₂O₃
• 分子量: 192.214
• InChiKey: SABTWEGVUYBBSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 过氧化氢苯甲酰 、 氯仿 作用下， 生成 2,3,4,5-Tetrahydro-1-benzoxepin-2-carbonsaeure
  参考文献：
  名称：

  570.芳香醚中分子构象和共轭的相互依赖性。第二部分

  摘要：

  DOI：

  10.1039/jr9580002797

文献信息

• Fused bicyclic carboxamide derivatives and methods of their use
  申请人：Dolle E. Roland

  公开号：US20050054630A1

  公开（公告）日：2005-03-10

  Fused bicyclic carboxamide derivatives are disclosed. Pharmaceutical compositions containing the compounds and methods for their use are also disclosed.

  揭示了融合的双环羧酰胺衍生物。还公开了含有这些化合物的药物组合物以及它们的使用方法。
• MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN
  申请人：AbbVie S.à.r.l.

  公开号：US20170305891A1

  公开（公告）日：2017-10-26

  The present invention provides for compounds of formula (I) wherein R 1 , m, Z, G 1 , R 2 , and R 3 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了以下式（I）的化合物，其中R1、m、Z、G1、R2和R3具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物可用作治疗由CFTR介导和调节的疾病和症状的药物，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病的药物。还提供了由一个或多个式（I）化合物组成的药物组合物。
• RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, COMPOUND, AND ACID DIFFUSION-CONTROLLING AGENT
  申请人：TOKYO OHKA KOGYO CO., LTD.

  公开号：US20220011665A1

  公开（公告）日：2022-01-13

  A resist composition that contains a base material component exhibiting changed solubility in a developing solution under action of acid and a compound (D0) represented by General Formula (d0), in which R 01 , R 02 , R 03 , and R 04 each independently represents a hydrogen atom, a hydroxy group, a halogen atom, or an alkyl group; alternatively, R 01 and R 02 , R 02 and R 03 , or R 03 and R 04 are bonded to each other to form an aromatic ring; R 05 represents a hydrogen atom or an alkyl group; Y represents a group that forms an alicyclic group together with a carbon atom *C; provided that at least one of the carbon atoms that form the alicyclic group is substituted with an ether bond, a thioether bond, a carbonyl group, a sulfinyl group, or a sulfonyl group; m represents an integer of 1 or more, and M m+ represents an m-valent organic cation

  一种抗蚀组合物，包含一种基础材料组分，在酸的作用下在显影溶液中表现出改变的溶解度，以及一种化合物（D0），其通式为（d0），其中R01、R02、R03和R04各自独立地代表氢原子、羟基、卤素原子或烷基；或者，R01和R02、R02和R03、或R03和R04彼此连接形成芳香环；R05代表氢原子或烷基；Y代表与碳原子*C一起形成脂环基的基团；前提是至少有一个形成脂环基的碳原子被醚键、硫醚键、羰基、亚磺酰基或磺酰基取代；m表示1或更多的整数，Mm+表示m价有机阳离子。
• Condensed seven-membered heterocyclic compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0205264A1

  公开（公告）日：1986-12-17

  Novel condensed seven-membered heterocyclic compounds of the formula: wherein R, and R2 are independently hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy, R3 and R4 are independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl or optionally substituted aralkyl, or both jointly form an optionally substituted ring together with the adjacent nitrogen atom, X is hydrogen, optionally substituted lower alkyl, optionally substituted aryl or a carboxyl group which may be esterified or amidated, Y is C=O or CH-OR5 in which Rs is hydrogen, acyl or optioinally substituted carbamoyl, A is an oxygen atom or sulfur atome, E is an oxygen atom or methylene, and G is lower alkylene, provided that when A is a sulfur atom, E is methylene, and salts thereof exhibit serotonin S2 receptor blocking activity, actions to relieve cerebral vasospasm and antithrombotic activity, and are of value as a prophylactic and therapeutic agent for ischemic cardiopathies, thrombosis, hypertension and cerebral circulatory disorders.

  式中的新型缩合七元杂环化合物： 其中 R 和 R2 独立地为氢、卤素、羟基、低级烷基或低级烷氧基、 R3和R4独立地为氢、任选取代的低级烷基、任选取代的环烷基或任选取代的芳烷基，或两者与相邻的氮原子共同形成任选取代的环、 X 是氢、任选取代的低级烷基、任选取代的芳基或可酯化或酰胺化的羧基、 Y 是 C=O 或 CH-OR5，其中 Rs 是氢、酰基或被选择取代的氨基甲酰基、 A 是氧原子或硫原子，E 是氧原子或亚甲基，以及 G 是低级亚烷基，条件是当 A 是硫原子时，E 是亚甲基、 及其盐类具有 5-羟色胺 S2 受体阻断活性、缓解脑血管痉挛的作用和抗血栓活性，具有作为 具有预防和治疗缺血性心脏病、血栓形成、高血压和脑循环障碍的价值。
• US7034051B2
  申请人：——

  公开号：US7034051B2

  公开（公告）日：2006-04-25